

I claim:

Sub
C1

1. A method for mitigating or ~~treating photophobia associated with migraine~~ to a patient in need thereof comprising:

5 providing an effective amount of ibuprofen, pharmaceutically acceptable salts thereof, isomers thereof, or mixtures thereof, as the sole pharmaceutically effective ingredients.

10 2. The method of claim 1 wherein the amount of ibuprofen, isomers thereof, or mixtures thereof, is from about 100 to about 800 milligrams per dosage.

15 3. The method of claim 1 wherein the amount of ibuprofen, isomers thereof, or mixtures thereof, is from about 200 to about 600 milligrams per dose.

Sub
C1

4. A method for mitigating or ~~treating phonophobia associated with migraine~~ to a patient in need thereof comprising:

20 providing an effective amount of ibuprofen, pharmaceutically acceptable salts thereof, isomers thereof, or mixtures thereof, as the sole pharmaceutically active ingredients.

25 5. The method of claim 4 wherein the amount of ibuprofen, isomers thereof, or mixtures thereof, is from about 100 to about 800 milligrams per dosage.

6. The method of claim 4 wherein the amount of ibuprofen, isomers thereof, or mixtures thereof, is from about 200 to about 600 milligrams per dose.

Sub
C1

7. The method of claim 1 wherein the amount of ibuprofen, pharmaceutically acceptable salts thereof, isomers thereof, or mixtures thereof, is about 200 milligrams per dose.

30 8. The method of claim 1 wherein the amount of ibuprofen, pharmaceutically acceptable salts thereof, isomers thereof, or mixtures thereof, is about 400 milligrams per dose.

9. The method of claim 4 wherein the amount of ibuprofen, pharmaceutically acceptable salts thereof, isomers thereof, or mixtures thereof, is about 200 milligrams per dose.

5 10. The method of claim 4 wherein the amount of ibuprofen, pharmaceutically acceptable salts thereof, isomers thereof, or mixtures thereof, is about 400 milligrams per dose.

11. The method of claim 1 wherein the pharmaceutically acceptable salts of ibuprofen are selected from the group consisting of:

- 10 a) inorganic cation salts;
b) organic salts of ibuprofen with pharmaceutically acceptable primary, secondary, tertiary, and quaternary amines; and
c) mixtures thereof.

15 12. The method of claim 1 wherein the pharmaceutically acceptable salt of ibuprofen is :

- a) an inorganic cation salt selected from sodium, potassium, lithium, magnesium, calcium, cesium, ammonia, ferrous, zinc, manganous, aluminum, ferric, and manganic;
b) an organic salt of ibuprofen with primary, secondary, tertiary and quaternary amines selected from triethylamine, tripropylamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, lysine, arginine, histidine, caffeine, procain, N-ethylpiperidine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, TRIS(hydroxymethyl)aminomethane, methylglycamine, theobromine, pruines, piperazine, piperidine, and polyamine resins; or
25 c) mixtures thereof.

Isomers
30 13. The method of claim 1 wherein the mixture is a mixture of ibuprofen and its potassium salt.

Isomers
14. The method of claim 1 wherein the isomer of ibuprofen is selected from the group consisting of R-ibuprofen, S-ibuprofen and mixtures thereof.

Sup
15. The method of claim 4 wherein the pharmaceutically acceptable salts of ibuprofen are selected from the group consisting of:

- a) inorganic cation salts;
- b) organic salts of ibuprofen with pharmaceutically acceptable primary, secondary, tertiary, and quaternary amines; and
- c) mixtures thereof.

5

16. The method of claim 4 wherein the pharmaceutically acceptable salt of ibuprofen is :

- a) an inorganic cation salt selected from sodium, potassium, lithium, magnesium, calcium, cesium, ammonia, ferrous, zinc, manganous, aluminum, ferric, and manganic;
- b) an organic salt of ibuprofen with primary, secondary, tertiary and quaternary amines selected from triethylamine, tripropylamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, lysine, arginine, histidine, caffeine, procain, N-ethylpiperidine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, TRIS(hydroxymethyl)aminomethane, methylglycamine, theobromine, prunes, piperazine, piperidine, and polyamine resins; or
- c) mixtures thereof.

10

15

20

17. The method of claim 4 wherein the mixture is a mixture of ibuprofen and its potassium salt.

18. The method of claim 4 wherein the isomer of ibuprofen is selected from the group consisting of R-ibuprofen, S-ibuprofen and mixtures thereof.

25

19. The method of claim 1 wherein the amount of the pharmaceutically acceptable salts of ibuprofen is from about 100 to about 1700 milligrams per dose.

20. The method of claim 4 wherein the amount of the pharmaceutically acceptable salts of ibuprofen is from about 100 to about 1700 milligrams per dose.

30

21. The method of claim 1 wherein the amount of the mixtures of ibuprofen, isomeres thereof, and pharmaceutically acceptable salts thereof is from about 100 to about 1700 milligrams per dose.

22. The method of claim 1 wherein the amount of the mixtures of ibuprofen, isomers thereof, and pharmaceutically acceptable salts thereof is from about 200 to about 1300 milligrams per dose.

5 23. The method of claim 4 wherein the amount of the mixtures of ibuprofen, isomers thereof, and pharmaceutically acceptable salts thereof is from about 100 to about 1700 milligrams per dose.

10 24. The method of claim 4 wherein the amount of the mixtures of ibuprofen, isomers thereof, and pharmaceutically acceptable salts thereof is from about 200 to about 1300 milligrams per dose.

15 25. A method for mitigating or treating photophobia associated with migraine to a patient in need thereof comprising:

providing an effective amount of ibuprofen as the sole pharmaceutically effective ingredient.

20 26. A method for mitigating or treating phonophobia associated with migraine to a patient in need thereof comprising:

providing an effective amount of ibuprofen as the sole pharmaceutically active ingredient.

add B1
add 1027